Particle.news
Download on the App Store

KALA BIO Says First AI Agent Ships in Two Weeks as Shares Soar Pre-Market

The company is refocusing on Researgency.ai to automate drug-development work for enterprise customers.

Overview

  • KALA says its first commercial AI agent will launch in about 14 days, with CEO Avi Minkowitz stating the team is ready to ship.
  • Pre-market trading jumped 69.68% with volume around 51 million shares, far above the roughly 1.94 million three-month daily average, after a 12.82% gain the prior session.
  • The first custom agent is being built with Younet’s AI engineering group, and KALA reports the Researgency.ai platform is live for enterprise access.
  • The firm frames its strategy as a 'Palantir for biotech' and targets workflows like research tracking, clinical documentation, regulatory compliance, safety reporting, and launch preparation.
  • Key details remain undisclosed, including pricing, the specific inaugural workflow, and customer commitments, while financial pressure persists with a roughly $8.3 million market cap, steep share declines, a $2 million Oxford Finance settlement, and the recent end of its Deloitte audit relationship.